Akèy › Kansè Endomèt › New Mexico › Albuquerque
Etid klinik pou Kansè Endomèt nan Albuquerque, NM
12 etid pou Kansè Endomèt ap chèche patisipan nan sit nan ak bò kote Albuquerque (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Ap rekriteFaz 3
- University of New Mexico Cancer Center, Albuquerque
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- University of New Mexico Cancer Center, Albuquerque
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Ap rekriteFaz 1
- University of New Mexico Cancer Center, Albuquerque
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Ap rekriteFaz 2
- University of New Mexico Cancer Center, Albuquerque
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Ap rekriteFaz 2
- Research Site, Albuquerque
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Ap rekriteFaz 3
- University of New Mexico Comprehensive Cancer Center ( Site 6046), Albuquerque
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Albuquerque
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Ap rekriteFaz 3
- Research Site, Albuquerque
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Ap rekriteFaz 2
- 292, Albuquerque
Uterine Preservation Via Lifestyle Transformation
Ap rekriteFaz 2
- University of New Mexico, Albuquerque
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Ap rekriteFaz 1
- University of New Mexico, Albuquerque
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Albuquerque
Etid Kansè Endomèt nan lòt vil
- Houston, TX68 etid
- New York City, NY52 etid
- Boston, MA50 etid
- Arlington, VA39 etid
- Nashville, TN38 etid
- Los Angeles, CA34 etid
- St. Louis, MO29 etid
- Philadelphia, PA28 etid
- San Antonio, TX27 etid
- Columbus, OH25 etid
- Oklahoma City, OK25 etid
- Chicago, IL25 etid
Lòt etid nan Albuquerque
- Kansè Poumon ki pa ti selil18 etid
- Kansè nan tete17 etid
- Kansè ovè15 etid
- Kansè (tout kalite)14 etid
- Kansè poumon14 etid
- Kansè Metastatik12 etid
- Dyabèt Tip 211 etid
- Maladi kadyovaskilè10 etid
- Melanom9 etid
- Leksemi mieloïd egi9 etid
- Kansè pwostat9 etid
- Maladi ren kwonik8 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.